Zobrazeno 1 - 10
of 434
pro vyhledávání: ''
Autor:
Jordi Remon, Benjamin Lacas, Roy Herbst, Martin Reck, Edward B. Garon, Giorgio V. Scagliotti, Rodryg Ramlau, Nasser Hanna, Johan Vansteenkiste, Kiyotaka Yoh, Harry J.M. Groen, John V. Heymach, Sumithra J. Mandrekar, Isamu Okamoto, Joel W. Neal, Rebecca S. Heist, David Planchard, Jean-Pierre Pignon, Benjamin Besse, B. Besse, B. Lacas, J.P. Pignon, J. Remon, T. Berghmans, S. Dahlberg, E. Felip, Thierry Berghmans, Suzanne Dahlberg, Enriqueta Felip, Edward Garon, Alex A. Adjei, Rebecca Heist
Publikováno v:
European Journal of Cancer. 166:112-125
BACKGROUND: Now that immunotherapy plus chemotherapy (CT) is one standard option in first-line treatment of advanced non-small cell lung cancer (NSCLC), there exists a medical need to assess the efficacy of second-line treatments (2LT) with antiangio
Autor:
Demetris Papamichael, Guilherme S. Lopes, Curt L. Olswold, Jean-Yves Douillard, Richard A. Adams, Timothy S. Maughan, Eric Van Cutsem, Alan P. Venook, Heinz-Josef Lenz, Volker Heinemann, Richard Kaplan, Carsten Bokemeyer, Benoist Chibaudel, Axel Grothey, Takayuki Yoshino, John Zalcberg, Aimery De Gramont, Qian Shi
Publikováno v:
European Journal of Cancer. 163:1-15
Colorectal cancer (CRC) affects many older adults. We investigated the efficacy and safety of adding anti-epidermal growth factor receptor (EGFR) agents to doublet chemotherapy (DC) in older patients.Patients with RAS wild-type (WT) metastatic CRC (m
Autor:
Diogo Assed Bastos, Juan Carlos Vazquez Limon, Lisa G. Horvath, Héctor Manuel Sánchez López, J.N. Minatta, Daniel Castellano, Margitta Retz, Jia Li, Fred Saad, Daniel P. Petrylak, Neha P. Amin, David R. Shaffer, Arash Rezazadeh Kalebasty, Keziban Unsal-Kacmaz, Andrew J. Armstrong, Russell K. Pachynski, Karim Fizazi, Pablo González Mella
Publikováno v:
European Journal of Cancer. 160:61-71
Background Docetaxel has immunostimulatory effects that may promote an immunoresponsive prostate tumour microenvironment, providing a rationale for combination with nivolumab (programmed death-1 inhibitor) for metastatic castration-resistant prostate
Autor:
Scott J. Diede, Michele Del Vecchio, Pier Francesco Ferrucci, Razi Ghori, Wilson H. Miller, Omid Hamid, Paolo A. Ascierto, Marcus O. Butler, Matteo S. Carlino, Antoni Ribas, Eduard Gasal, Elaine McWhirter, Robert Zielinski, Elizabeth Croydon, Michele Maio, Anthony M. Joshua
Publikováno v:
European Journal of Cancer. 160:1-11
OBJECTIVES Parts 4 and 5 of the phase 1/2 KEYNOTE-022 study investigated the maximum tolerated dose (MTD), safety, and efficacy of pembrolizumab plus trametinib in solid tumours and BRAF wild-type melanoma. PATIENTS AND METHODS Patients received inte
Autor:
Yoshiaki Murakami, Shingo Seo, Hiroyuki Otsuka, Yasushi Hashimoto, Naru Kondo, Shinya Takahashi, Takeshi Sudo, Kenjiro Okada, Tatsuaki Sumiyoshi, Kenichiro Uemura
Publikováno v:
European Journal of Cancer. 159:215-223
Background The prognosis of patients with borderline resectable pancreatic cancer with arterial contact (BRPC-A) is extremely poor, and effective preoperative treatment is indispensable. We evaluated the clinical efficacy and safety of neoadjuvant ch
Autor:
Neal D. Shore, Joyce Steinberg, Bertrand Tombal, Ugo De Giorgi, Xun Lin, Qi Shen, Fred Saad, David F. Penson, Katarzyna Madziarska, Jennifer Sugg, Cora N. Sternberg, Eleni Efstathiou, Maha Hussain, Karim Fizazi
Publikováno v:
European journal of cancer, Vol. 159, p. 237-246 (2021)
BACKGROUND: Enzalutamide combined with androgen deprivation therapy (ADT) significantly prolonged metastasis-free survival and overall survival (OS) versus ADT alone in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) with r
Autor:
Guilherme Cantuaria, Paul DiSilvestro, Kirsty Rhodes, Lucy Gilbert, Johanna Mäenpää, Christian Marth, Maria Jesus Rubio Pérez, Koji Matsumoto, Claire Garnier-Tixidre, Ayumi Shikama, Isabelle Ray-Coquard, Philipp Harter, Daniel M. Anderson, Magdalena Sikorska, Francesco Raspagliesi, Ignace Vergote, Mario Ouwens, Robert Hettle, Domenica Lorusso, Kathleen N. Moore, Andres Poveda, Nicoletta Colombo, Ronnie Shapira-Frommer
Publikováno v:
European Journal of Cancer. 157:415-423
BACKGROUND: In the absence of randomised head-to-head trials, we conducted a population-adjusted indirect treatment comparison (PA-ITC) of phase III trial data to evaluate the relative efficacy and safety of maintenance olaparib and bevacizumab alone
Autor:
In Gyu Hwang, Sang-Cheol Lee, Yaewon Yang, Sung Yong Oh, Sang-Gon Park, So Yeon Jeon, Dae Young Zang, Jung Hun Kang, Jun Ho Ji, Hyun Woo Lee, Woo Kyun Bae, Sun Jin Sym, Se-Il Go, Joung Soon Jang, Jung Hoon Kim
Publikováno v:
European Journal of Cancer. 157:21-30
Background The efficacy of modified FOLFIRINOX (mFOLFIRINOX) as a second-line chemotherapy treatment for metastatic pancreatic adenocarcinoma (mPAC), remains unclear. This multi-center randomised phase III trial aimed to elucidate the efficacy of mFO
Autor:
Clemens Gießen-Jung, Thomas Decker, Andreas Jung, Ullrich Graeven, Jens Neumann, Ingo Schwaner, A. Stahler, Annika Kurreck, Thomas Kirchner, Dominik Paul Modest, Michael Schenk, Veronika Schuster, C. Denzlinger, Kathrin Heinrich, Volker Heinemann, Swantje Held, Florian Kaiser, Ludwig Fischer von Weikersthal, Jörg Kumbrink, Sebastian Stintzing
Publikováno v:
European Journal of Cancer. 157:71-80
Background The XELAVIRI trial compared sequential (fluoropyrimidine and bevacizumab; irinotecan (Iri) at progression) versus initial combination therapy (fluoropyrimidine, bevacizumab, Iri) of treatment-naive metastatic colorectal cancer (mCRC). In t
Autor:
Shi Ming Tu, Sumit K. Subudhi, Ana Aparicio, Ioannis Alafis, Brian F. Chapin, Xuemei Wang, Myrto Boukovala, Paul G. Corn, Nicholas Spetsieris, John C. Araujo, Justin A. Weldon, Eleni Efstathiou, Jennifer Wang, Lisa Pruitt, Christopher J. Logothetis, Amado J. Zurita, John Papadopoulos, John J. Davis
Publikováno v:
European Journal of Cancer. 157:259-267
Background Intermittent androgen deprivation therapy (ADT) in biochemically recurrent castration-naive prostate cancer is non-inferior to continuous therapy. We hypothesised that finite-duration abiraterone acetate plus prednisone (Abi +P) added to A